GoldenGolden
Genentech

Genentech

Biotechnology company that discovers, develops, manufactures and commercializes therapeutic products for serious or life-threatening medical conditions. Disease areas include oncology, immunology, ophthalmology, metabolism and virology. Genentech has been a member of the Roche Group since 2009.

In 2009 Genentech became a member of the Roche Group and the two companies combined their pharmaceutical operations in the US. The San Francisco campus of Genentech serves as headquarters for Roche pharmaceutical operations in the US. Operating as an independent center within Roche is Genentech Research and Early Development.

Genentech was founded by Robert A. Swanson (1947-1999), a venture capitalist, and biochemist Dr. Herbert W. Boyer. Boyer along with Stanley Cohen were pioneers in recombinant DNA technology.

Genetech has drug manufacturing facilities in South San Francisco, Vacaville and Oceanside, California. Genetech focused on large-scale biologics and products for about 30 years. A shift towards developing therapies that target smaller patient populations began around 2013. Genentech has two commercial large volume products, Herceptin and Rituxan, of which they produce more than 2000 kg per year. The company has six products that classify as standard volume products, between 300 kg and 2000 kg per year, as well as three in clinical trials. As of 2019 Genetech had four products considered small volume, less than 300 kg per year, and nine small volume products in the pipeline.

Genentech is developing a virtual reality simulator for eye surgery.

Products
Biooncology

Alecensa® (alectinib)

Avastin® (bevacizumab)

Cotellic® (cobimetinib)

Erivedge® (vismodegib)

Gazyva® (obinutuzumab)

Herceptin® (trastuzumab)

Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk)

Kadcyla® (ado-trastuzumab emtansine)

Perjeta® (pertuzumab)

Rituxan® (rituximab [Oncology])

Rituxan Hycela™ (rituximab and hyaluronidase human)

Tarceva® (erlotinib)

Tecentriq® (atezolizumab)

Venclexta® (venetoclax)

Xeloda® (capecitabine)

Zelboraf® (vemurafenib)

Immunology and Ophthalmology

Actemra® (tocilizumab)

Esbriet® (pirfenidone)

Lucentis™ (ranibizumab injection)

Rituxan® (rituximab [Immunology])

Xolair® (omalizumab)

Metabolism and Primary Care

Activase® (alteplase)

Cathflo Activase® (alteplase)

Nutropin AQ® (somatropin (rDNA origin) for injection)

TNKase® (tenecteplase)

Neurology

Ocrevus® (ocrelizumab)

Virology and Specialty Care

CellCept® (mycophenolate mofetil)

Pegasys® (peginterferon alfa-2a)

Pulmozyme® (dornase alfa)

Tamiflu® (oseltamivir phosphate)

Valcyte® (valganciclovir hydrochloride)

Xofluza ™ (baloxavir marboxil)

Other

Boniva Injection® (ibandronate sodium)

Boniva Tablets® (ibandronate sodium)

Cytovene® (ganciclovir)

Fuzeon® (enfuvirtide)

Hemlibra® (emicizumab-kxwh)

Invirase® (saquinavir mesylate)

Klonopin® (clonazepam)

Valium® (diazepam)

Timeline

November 23, 2020
OneOncology and Genentech announce the first clinical trial available to patients through OneR, the OneOncology Research Network.
May 18, 2020
Flatiron Health, Foundation Medicine, and Genentech partner to launch Novel Prospective Lung Cancer Clinical Study.
1976
Genentech raises a $100,000 seed round from Kleiner Perkins Caufield & Byers.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Genentech Seed round, 1976
100,000
1976
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

aakanksha patel

Employee

Aaron Yip

Employee

Aashima Singhal

Founder

Abraham Gacad

Employee

Adam Tomashek

Employee

Adhithya Mohanraj

Employee

Adilet Matkerimov

Employee

Adrian Jubb

Employee

Adriana Delor

Employee

Ajay Kshatriya

Employee

AKASH ARYA

Employee

Akila Gopalakrishnan

Employee

Akila Subramanian

Employee

Akiyo Marukawa

Previous Employee

Alan C Pikna

Employee

Alan Pruitt

Employee

Alec Howard

Employee

Alefiyah Shambhoora

Employee

Alekhya Akkunuri

Employee

Alex Bash

Employee

Alex Fischer

Employee

Alex Pomerantz

Employee

Alex Smoligovets

Employee

Alexander Kislukhin

Employee

Alexander Kozintsev

Employee

Page 1 of 27
...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Mark Terry
May 14, 2021
BioSpace
Life science jobs are booming in several regions around the U.S. One is the Pacific Northwest, specifically Oregon; another is the Philadelphia area. Here's a look.
Mark Terry
May 14, 2021
BioSpace
Life science jobs are booming in several regions around the U.S. One is the Pacific Northwest, specifically Oregon; another is the Philadelphia area. Here's a look.
Curis, Inc.
May 12, 2021
www.prnewswire.com:443
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
DelveInsight Business Research, LLP
May 12, 2021
www.prnewswire.com:443
/PRNewswire/ -- DelveInsight's Diabetic Retinopathy Market Insights report offers detailed information on current treatment practices, emerging drugs, Diabetic...
Curis, Inc.
May 12, 2021
www.prnewswire.com:443
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Alex Keown
April 28, 2021
BioSpace
A U.S. FDA committee gave the nod to continue using Genentech's checkpoint inhibitor Tecentriq in combination with chemotherapy to treat adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1.
Alex Keown
April 28, 2021
BioSpace
A U.S. FDA committee gave the nod to continue using Genentech's checkpoint inhibitor Tecentriq in combination with chemotherapy to treat adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1.
April 27, 2021
BioSpace
Graphite Bio Appoints Jane Grogan, Ph.D., as Chief Scientific Officer - read this article along with other careers information, tips and advice on BioSpace
Amirah Al Idrus
April 21, 2021
FierceBiotech
Sushil Patel, the Genentech executive who led the development of Tecentriq in lung cancer, is turning his focus to oncolytic, or cancer-killing, viruses. He joins Replimune, a biotech working on treatments designed not just to replicate within tumors and kill them, but also boost the effects of checkpoint inhibitors like Tecentriq.
BioSpace
April 21, 2021
BioSpace
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its ImmulyticTM platform, today announced the strengthening of its executive team with the appointment of Sushil Patel, Ph.D. as Replimune's Chief Commercial Officer effective May 3, 2021
April 21, 2021
BioSpace
Cedilla Therapeutics Appoints Chris Bowden, M.D. to its Board of Directors - read this article along with other careers information, tips and advice on BioSpace
Alex Keown
April 16, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace
April 15, 2021
BioSpace
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021.
Alex Keown
April 13, 2021
BioSpace
The U.S. Food and Drug Administration (FDA) approved a prefilled syringe for self-injection of an allergic diseases treatment developed by Novartis and Genentech, a Roche company.
Curis, Inc.
March 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Nick Paul
February 26, 2021
FierceBiotech
Genentech has partnered with the University of California (UC), San Francisco and UC Berkeley to work on neuroscience drugs. The Roche subsidiary has committed up to $53 million to collaborate with the academics on areas such as neurodegeneration over the next 10 years.
Nick Paul
January 11, 2021
FierceBiotech
Atalanta Therapeutics has broken cover with $110 million from a series A round and partnerships with Biogen and Genentech. The biotech secured the deals and funding on the strength of evidence it can durably silence genes in the brain.
Amirah Al Idrus
December 18, 2020
FierceBiotech
It seems like a no-brainer. If a company wants to treat everyone who has a certain disease with its new drug, then it should test that drug in, well, everyone.
Nick Paul
December 14, 2020
FierceBiotech
Genentech has struck a deal to license Relay Therapeutics' SHP2 inhibitor for $75 million upfront. The Roche subsidiary plans to combine the drug with its KRAS G12C inhibitor, reflecting evidence targeting SHP2 counters adaptive resistance to the red-hot approach to treating cancer.
BioSpace
December 1, 2020
BioSpace
FibroGen, Inc. (NASDAQ: FGEN) today announced the retirement of K. Peony Yu, M.D., Chief Medical Officer, and appointment of Mark Eisner, M.D., M.P.H. in that role. Dr. Yu will continue as Chief Medical Officer through December 20, 2020, the roxadustat PDUFA date, and will remain with FibroGen through March 15, 2021 serving as Executive Advisor to the CEO to support the transition. Dr. Yu joined FibroGen in 2008 and has provided key leadership
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.